Research Ethics Board Approves Amendment to Canadian COVID-19 Treatment Trial to Include LSALT Peptide

Arch Biopartners Inc., a clinical stage company focused on developing new drug candidates for treating organ damage caused by inflammation, announced that the Research Ethics Board at the Sunnybrook Research Institute has approved an amendment to the CATCO protocol. This amendment includes the company's lead drug candidate, LSALT Peptide (also known as Metablok), in a new arm of the CATCO human trial.

The CATCO leadership is now set to seek Health Canada approval before commencing the dosing of LSALT in the new arm of the trial. This development marks a significant step forward in the research and potential treatment options for COVID-19 related organ damage, leveraging the anti-inflammatory properties of LSALT Peptide.